Abingdon, United Kingdom

Jac C Wijkmans

This inventor holds 2 USPTO granted patents. Top assignee: Other. Active years: 2005-2007.


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:

goldMedal2 out of 834,411 
Other
 patents

Years Active: 2005-2007

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Jac C Wijkmans

Introduction

Jac C Wijkmans is a notable inventor based in Abingdon Oxon, GB. He has made significant contributions to the field of pharmaceutical compositions, particularly in the area of anti-apoptotic agents. With a total of 2 patents, Wijkmans has focused on developing compositions that utilize lysophosphatidic acids.

Latest Patents

Wijkmans' latest patents include compositions containing lysophosphatidic acids that inhibit apoptosis and their various uses. The invention provides anti-apoptotic compositions that contain lysophosphatidic acids along with methods for making and using these compositions. These compositions may also include LPA potentiating agents, such as proteins, lipid membrane structures, and polymers like polyethylene glycols. Additionally, they can contain other pharmaceutically effective agents, including drugs, antibiotics, wound healing agents, and antioxidants.

Career Highlights

Throughout his career, Wijkmans has demonstrated a commitment to advancing medical science through his innovative work. His patents reflect a deep understanding of biochemistry and the potential therapeutic applications of his inventions.

Collaborations

Wijkmans has collaborated with notable individuals in his field, including John G Goddard and Donald H Picker. These collaborations have likely contributed to the development and refinement of his innovative compositions.

Conclusion

Jac C Wijkmans is a distinguished inventor whose work in anti-apoptotic compositions has the potential to impact the pharmaceutical industry significantly. His contributions continue to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…